(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
This research study is looking at a new medication called bezuclastinib for adults suffering from advanced systemic mastocytosis (AdvSM). This includes specific types such as aggressive systemic mastocytosis (ASM), systemic mastocytosis with another blood cancer (SM-AHN), and mast cell leukemia (MCL). The main goal is to find out how safe the drug is and if it can help improve the condition. The study is called an 'open-label' study, which means both you and the study doctors will know you are receiving bezuclastinib. This is a Phase 2 study, meaning the drug has already been tested for safety in a small number of people, and now researchers want to learn more about its effects in a larger group of patients.
Auf einen Blick
Worum geht es in dieser Studie?
This study is about an important new medicine called bezuclastinib, which is being tested for people who have advanced systemic mastocytosis (AdvSM). This is a rare condition where certain blood cells, called mast cells, build up too much in the body and can cause serious health problems. The study focuses on the more serious forms of this condition, including aggressive systemic mastocytosis, mastocytosis with another blood cancer, and a very rare type called mast cell leukemia.
Researchers want to see if bezuclastinib can help control these mast cells and improve symptoms for patients. Because mastocytosis is a complex condition, developing new treatments is really important to help improve patients' lives. This study is a 'Phase 2' study, which means that the medicine has already been found to be safe enough to test in a larger group of people, and now the scientists want to get a better idea of how well it works and if it has any side effects.
The study is 'open-label,' which means everyone involved – the patients and the doctors – will know that the study medicine being given is bezuclastinib. This type of study design helps researchers gather information efficiently about the drug's effects. The findings from this research could potentially lead to a new treatment option for people living with these challenging forms of mastocytosis.
Wichtige Erkenntnisse
- This study is for adults with advanced systemic mastocytosis.
- It tests a new medicine called bezuclastinib.
- The study aims to check how safe and effective the medicine is.
- It's an 'open-label' study, meaning everyone knows you're getting the study drug.
- Regular health checks and blood tests will be part of the study.
- Sie können die Teilnahme jederzeit beenden.
Wer könnte berechtigt sein?
To join this study, you need to be an adult (18 years or older) and have one of the more advanced forms of mastocytosis (aggressive systemic mastocytosis, mastocytosis with another blood cancer, or mast cell leukemia). Doctors will need to confirm your diagnosis. You also need to have signs of the disease that can be measured, and your general health, including your heart, should be stable enough to take part. Your recent blood test results also need to be within certain acceptable ranges.
There are also reasons why you might not be able to join. For example, if you still have serious side effects from previous mastocytosis treatments, or if you need immediate treatment for another blood cancer. You can't have certain heart conditions or have had serious bleeding recently. If you have HIV, Hepatitis B, or Hepatitis C, or certain other cancers, you wouldn't be able to participate. Also, if you've recently had other cancer treatments, certain medications, or specific types of growth factors, you might need to wait before joining.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Have you been diagnosed with aggressive systemic mastocytosis, mastocytosis with another blood cancer, or mast cell leukemia?
- Is your general health, including your heart, currently stable?
- Have you spoken with your doctor about any recent treatments or serious medical conditions you have?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you will be given the study medicine, bezuclastinib. The study is open-label, meaning everyone will know you are taking the study drug. You will have regular visits to the clinic so the study team can monitor your health, check how the medicine is working, and look for any side effects. This will involve regular blood tests, physical examinations, and possibly other tests to see how your mastocytosis is responding to the treatment. You might also be asked to complete questionnaires about how you are feeling.
The total duration of your participation in the study will depend on how you respond to the treatment and the study’s protocol. There will be an initial treatment period, followed by ongoing monitoring. You will be able to stop participating in the study at any time if you wish to, for any reason, without it affecting your usual medical care.
Potenzielle Risiken und Vorteile
Standorte (42)
- Krankenhaus der Universität von Alabama in Birmingham (UAB)Verifizierte PostleitzahlBirmingham, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Mayo Clinic ArizonaVerifizierte PostleitzahlPhoenix, Vereinigte Staaten· Rekrutierung
- City of Hope Comprehensive Cancer CenterVerifizierte PostleitzahlDuarte, Vereinigte Staaten· Rekrutierung
- UCLA Medizinisches ZentrumVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Rekrutierung
- Stanford Cancer InstituteVerifizierte PostleitzahlStanford, Vereinigte Staaten· Rekrutierung
- Galiz ResearchVerifizierte PostleitzahlHialeah, Vereinigte Staaten· Zurückgezogen
- Winship Cancer Institute - Emory UniversityVerifizierte PostleitzahlAtlanta, Vereinigte Staaten· Rekrutierung
- Rush UniversitätsklinikumVerifizierte PostleitzahlChicago, Vereinigte Staaten· Zurückgezogen
- Dana-Farber Cancer InstituteVerifizierte PostleitzahlBoston, Vereinigte Staaten· Rekrutierung
- Columbia University Irving Medical CenterVerifizierte PostleitzahlNew York, Vereinigte Staaten· Zurückgezogen
- Cleveland Clinic Taussig Cancer CenterVerifizierte PostleitzahlCleveland, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- MUSC Health University Medical CenterVerifizierte PostleitzahlCharleston, Vereinigte Staaten· Rekrutierung
Häufige Fragen
What is systemic mastocytosis?
Systemic mastocytosis is a rare condition where too many mast cells, a type of immune cell, build up in your body's tissues and organs.
What is an 'advanced' form of mastocytosis?
Advanced forms of mastocytosis are more serious types of the condition, where the mast cells can cause more significant health problems or organ damage.
What does 'open-label' mean in a study?
Open-label means that both you and the study doctors will know that you are receiving the study medication, bezuclastinib.
Was ist eine Phase-2-Studie?
A Phase 2 study tests a medicine in a larger group of patients after it has been shown to be safe in a smaller group. The goal is to see how well it works and to learn more about side effects.
Muss ich bezahlen, um an dieser Studie teilzunehmen?
No, you will not have to pay for the study drug or study-related tests and procedures. These costs are covered by the research study.
Wie Sie mehr erfahren können
Cogent Biosciences, Inc.
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.